检索历史 清除

目的:探讨LncRNA-TUG1在脂多糖（LPS）诱导的小肠黏膜上皮细胞损伤中的作用和机制。方法:使用LPS处理HIEC-6人类小肠黏膜上皮细胞24 h构建脓毒症损伤模型。全转录组RNA测序分析LPS处理后HIEC-6细胞中的mRNA、microRNA及lncRNA表达变化。实时荧光定量（qRT-PCR）及western blot检测LncRNA-TUG1、microRNA-132-3p（miR-132-3p）、SIRT1 mRNA及SIRT1蛋白的表达在LPS处理后HIEC-6细胞中的表达变化。体外转染技术改变LncRNA-TUG1、microRNA-132-3p及SIRT1的表达水平。qRT-PCR及western blot分析LncRNA-TUG1对miR-132-3p及SIRT1的表达调控。CCK-8及流式细胞术分析LncRNA-TUG1、miR-132-3p及SIRT1对HIEC-6细胞增殖和凋亡的影响。双荧光素酶报告分析验证LncRNA-TUG1、miR-132-3p及SIRT1之间的靶向关系。统计学分析采用SPSS 17.0进行，两组间的差异比较采用独立样本 t检验。 结果:RNA测序结果显示LPS处理后的HIEC-6细胞中出现LncRNA-TUG1及SIRT1表达降低（ t=3.26， P<0.05以及 t=2.55， P<0.05），但是miR-132-3p表达升高（ t=4.12， P<0.05）。在体外细胞实验中，LPS处理后HIEC-6细胞后，LncRNA-TUG1及SIRT1表达降低（ t=5.69， P<0.05以及 t=5.712， P<0.05），而miR-132-3p表达升高（ t=3.88， P<0.05）。LncRNA-TUG1过表达能够增加LPS处理后细胞的增殖率（ t=6.55， P<0.05）同时降低其凋亡率（ t=3.94， P<0.05）。上调LncRNA-TUG1可以降低miR-132-3p的表达（ t=4.66， P<0.05），同时增加SIRT1 mRNA（ t=3.91， P<0.05）及蛋白的水平。转染miR-132-3p mimic可以抑制SIRT1 mRNA（ t=4.08， P<0.05）及蛋白的水平。在LPS处理的细胞中，与仅转染pcDNA3.1-LncRNA-TUG的细胞相比，共转染miR-132-3pmimic和siRNA-SIRT1的细胞增殖率较低（ t=4.55， P<0.05以及 t=5.67， P<0.05），凋亡率较高 t=3.90， P<0.05以及 t=4.22， P<0.05）。 结论:lncRNA-TUG1可能作为ceRNA调控miR-132-3p /SIRT1从而减轻LPS造成的HIEC-6细胞损伤。干预lncRNA-TUG1/microRNA-132-3p/SIRT1调控通路可能成为防治脓毒症引起小肠损伤的潜在策略。

Objective:To investigate the role of LncRNA-TUG1 in the injury of intestinal epithelial cells induced by lipopolysaccharide (LPS).Methods:LPS was used to treat HIEC-6 human intestinal epithelial cells for 24 h to construct a sepsis injury model. Whole transcriptome RNA sequencing was used to analyze the expression changes of mRNA, microRNA and lncRNA in HIEC-6 cells after LPS treatment. Real-time fluorescence quantitative (qRT-PCR) and Western blot was performed to detect the expression changes of lncRNA-TUG1, microRNA-132-3p (miR-132-3p), SIRT1 mRNA and SIRT1 protein in HIEC-6 cells after LPS treatment. The expression levels of LncRNA-TUG1, miR-132-3p and SIRT1 were artificially changed by in vitro transfection. qRT-PCR and Western blot were used to confirm the regulatory effect of lncRNA-TUG1 on microRNA-132-3p and SIRT1. CCK-8 and flow cytometry were used to analyze the effects of LncRNA-TUG1, miR-132-3p and SIRT1 on the proliferation and apoptosis of HIEC-6 cells. The dual luciferase report analysis was used to verify the targeting relationship between LncRNA-TUG1, miR-132-3p and SIRT1. Statistical analysis was performed using SPSS 17.0, and differences between the two groups were compared using independent sample t test. Results:RNA sequencing results showed that the expressions of lncRNA-TUG1 and SIRT1 were decreased in HIEC-6 cells after LPS treatment ( t=3.26, P<0.05 and t=2.55, P<0.05), but the expression of miR-132-3p was increased ( t=4.12, P<0.05). In vitro cell experiments, the expression of lncRNA-TUG1 and SIRT1 were decreased in HIEC-6 cells treated with LPS ( t=5.69, P<0.05 and t=5.712, P<0.05), while the expression of miR-132-3p was increased ( t=3.88, P<0.05). Overexpression of lncRNA-TUG1 increased the proliferation rate ( t=6.55, P<0.05) and decreased the apoptosis rate ( t=3.94, P<0.05) of LPS-treated cells. Upregulation of lncRNA-TUG1 decreased the expression of miR-132-3p ( t=4.66, P<0.05), and increased the mRNA and protein levels of SIRT1 ( t=3.91, P<0.05). Transfection of miR-132-3P mimic could inhibit the mRNA ( t=4.08, P<0.05) and protein levels of SIRT1. In LPS-treated cells, the cells co-transfected with miR-132-3pmimic and siRNA-SIRT1 had a lower proliferation rate ( t=4.55, P<0.05 and t=5.67, P<0.05) and a higher apoptosis rate ( t=3.90, P<0.05 and t=4.22, P<0.05) than those transfected with only pcDNA3.1-lncRNA-TUG. Conclusions:lncRNA-TUG1 may act as a ceRNA to regulate miR-132-3p/SIRT1, therefore alleviating HIEC-6 cell injury caused by LPS. Intervention of lncRNA-TUG1/miR-132-3p/SIRT1 regulatory pathway may become a potential strategy to prevent sepsis-induced intestinal mucosal damage.